Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

3(37.5%)

N/A

2(25.0%)

Phase 1

2(25.0%)

Phase 3

1(12.5%)

8Total

Phase 4(3)

N/A(2)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07272434Phase 3Recruiting

Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

Role: collaborator

NCT05050474Phase 1Completed

Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

Role: collaborator

NCT05079152Phase 4Unknown

Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4

Role: collaborator

NCT03274102Phase 4Completed

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines

Role: collaborator

NCT02796963Not ApplicableCompleted

Crowdsourcing A Public Health Campaign

Role: collaborator

NCT03296410Phase 4Unknown

The Phase IVd of Inactivated Enterovirus 71 Vaccine

Role: collaborator

NCT02643446Completed

Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine

Role: collaborator

NCT03125993Not ApplicableUnknown

Effects of Brisk Walking on Overweight/Obesity Population

Role: lead

NCT02919293Phase 1Unknown

Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age

Role: collaborator

All 9 trials loaded